InvestorsObserver
Sign Up Login

ELYM Eliem Therapeutics Inc

$3.21 $0.00 (0.00%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

ELYM Stock Analysis Overview

What this means: InvestorsObserver gives Eliem Therapeutics Inc (ELYM) an overall rank of 44, which is below average. Eliem Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 44 means that 56% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ELYM Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ELYM Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ELYM Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ELYM Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ELYM Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ELYM Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ELYM Stock Analysis Overview

What this means: InvestorsObserver gives Eliem Therapeutics Inc (ELYM) an overall rank of 44, which is below average. Eliem Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 44 means that 56% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ELYM report

ELYM Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ELYM Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ELYM Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ELYM Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ELYM Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ELYM Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Eliem Therapeutics Inc (ELYM) Analyst Forecast

ELYM Price, Volume, Earnings, and Dividend Date

  • Last Price $3.21
  • Previous Close $3.21
  • Change $0.00
  • Open $3.21
  • Volume 905
  • Avg. Volume (100-day) 13,187
  • Market Cap 85,282,256
  • Days Range 3.21 - 3.21
  • 52-week Range 2.21 - 9.51
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 05/15/23
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 1.725
  • PEG Ratio —

Eliem Therapeutics Inc (ELYM) Company Description

Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.

Eliem Therapeutics Inc (ELYM) Stock Chart

View Interactive ELYM chart

My Watchlists

Top Stocks in Biotechnology